Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sabine Cenciarelli is active.

Publication


Featured researches published by Sabine Cenciarelli.


Annals of Surgical Oncology | 2009

Full Robotic Left Colon and Rectal Cancer Resection: Technique and Early Outcome

Fabrizio Luca; Sabine Cenciarelli; Manuela Valvo; Simonetta Pozzi; Felice Lo Faso; D. Ravizza; Giulia Zampino; Angelica Sonzogni; Roberto Biffi

AbstractObjectiveThe technique for robotic resection of the left colon and anterior resection of the rectum with total mesorectal excision is not well defined. In this study we describe a method that standardizes robot and trocar position, and allows for a complete mobilization of the left colon and the rectum, without repositioning of the surgical cart. Outcome and pathology findings are also reported. MethodsFrom January 2007 to May 2008 a total of 55 consecutive patients affected by rectal and left colon cancer were operated on, with full robotic technique, using the Da Vinci robot. Data regarding outcome and pathology reports were prospectively collected in a dedicated database.ResultsThe following procedures were performed 27 left colectomies, 17 anterior resections, 4 intersphincteric resections, 7 abdominoperineal resections. There were 21 female and 34 male patients with a mean age of 63 ± 9.9 years. Mean operative time was 290 ± 69 minutes, ranging from 164 to 487 min., none were converted to open surgery. The median number of lymph nodes harvested was 18.5 ± 8.3 (range 5-45), and circumferential margin was negative in all cases. Distal margin was 25.15 ± 12.9 mm (range 6-55) for patients with rectal cancer, and 31.6 ± 20 mm for all the patients in this series. Anastomotic leak rate was 12.7% (7/55); in all cases conservative treatment was successful.ConclusionsFull robotic colorectal surgery is a safe and effective technique that exploits the advantages of the Da Vinci robot during the whole intervention, without the need to make use of hybrid operations. Outcome and pathology findings are comparable with those observed in open and laparoscopy procedures.


Ejso | 2011

Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection

Roberto Biffi; E. Botteri; Sabine Cenciarelli; Fabrizio Luca; Simonetta Pozzi; Manuela Valvo; Angelica Sonzogni; A. Chiappa; T. Leal Ghezzi; Nicole Rotmensz; V. Bagnardi; Bruno Andreoni

PURPOSE This study was designed to establish whether the number of lymph nodes removed has an effect on prognosis in patients with node-negative gastric cancer. PATIENTS AND METHODS We retrospectively analysed data of 114 consecutive patients who underwent gastrectomy and extended lymph node dissection for node-negative adenocarcinoma of the stomach between 2000 and 2005. Standard survival methods and restricted cubic spline multivariable Cox regression models were applied. RESULTS Median age was 63 years and 67 patients out of 114 (59%) were males. Median number of dissected LNs was 22 (range 2-73). Median follow-up was 76 months. Patients who had ≤15 nodes removed had significantly worse distant disease-free survival, disease-free survival and overall survival at multivariable analysis than other patients. The results did not change when pT1 and pT2-3 cancer patients were analysed separately. The risk of distant metastases decreased as the number of dissected lymph nodes increased (>15). CONCLUSIONS More extended lymph node resection offered survival benefit even in the subgroup of patients with early stage disease. Lymphadenectomy involving more than 15 lymph nodes should be performed for the treatment of node-negative gastric cancer. SYNOPSIS The impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer has not been established. This study suggests that more extended lymph node resection offers protection, as patients who had ≤15 nodes removed had significantly worse disease-free survival and overall survival at multivariate analysis than patients in whom >15 nodes were removed.


Ejso | 2014

Robotic versus open total mesorectal excision for rectal cancer: Comparative study of short and long-term outcomes

Tiago Leal Ghezzi; Fabrizio Luca; Manuela Valvo; O.C. Corleta; M. Zuccaro; Sabine Cenciarelli; Roberto Biffi

BACKGROUND Despite the several series in which the short-term outcomes of robotic-assisted surgery were investigated, data concerning the long-term outcomes are still scarce. METHODS The prospectively collected records of 65 consecutive patients with extraperitoneal rectal cancer who underwent robotic total mesorectal excision (RTME) were compared with those of 109 consecutive patients treated with open surgery (OTME). Patient characteristics, pathological findings, local and systemic recurrence rates and 5-year survival rates were compared. RESULTS There were no statistically significant differences in postoperative complications, reoperation and 30-day mortality. There were significant differences comparing groups: number of lymph nodes harvested (RTME: 20.1 vs. OTME: 14.1, P < 0.001), estimated blood loss (RTME: 0 vs. OTME: 150 ml, P = 0.003), operation time (RTME: 299.0 vs. OTME: 207.5 min, P < 0.001) and length of postoperative stay (RTME: 6 vs. OTME: 9 days, P < 0.001). The rate of circumferential resection margin involvement and distal resection margin were not statistically different between groups. There were no statistically significant differences at the 5-year follow-up: overall survival, disease-free survival and cancer-specific survival. The cumulative local recurrence rate was statistically lower in the robotic group (RTME: 3.4% vs. OTME: 16.1%, P = 0.024). CONCLUSION RTME showed a significant reduction in local recurrence rate and a higher, although not statistically significant, long-term cancer-specific survival with respect to OTME. Prospective randomized studies are needed to confirm or deny significantly better local control rates with robotic surgery.


World Journal of Surgical Oncology | 2012

Surgical site infections following colorectal cancer surgery: a randomized prospective trial comparing common and advanced antimicrobial dressing containing ionic silver

Roberto Biffi; Luca Fattori; Emilio Bertani; Davide Radice; Nicole Rotmensz; Pasquale Misitano; Sabine Cenciarelli; Antonio Chiappa; Liliana Tadini; Marina Mancini; Giovanni Pesenti; Bruno Andreoni; Angelo Nespoli

BackgroundAn antimicrobial dressing containing ionic silver was found effective in reducing surgical-site infection in a preliminary study of colorectal cancer elective surgery. We decided to test this finding in a randomized, double-blind trial.MethodsAdults undergoing elective colorectal cancer surgery at two university-affiliated hospitals were randomly assigned to have the surgical incision dressed with Aquacel® Ag Hydrofiber dressing or a common dressing. To blind the patient and the nursing and medical staff to the nature of the dressing used, scrub nurses covered Aquacel® Ag Hydrofiber with a common wound dressing in the experimental arm, whereas a double common dressing was applied to patients of control group. The primary end-point of the study was the occurrence of any surgical-site infection within 30 days of surgery.ResultsA total of 112 patients (58 in the experimental arm and 54 in the control group) qualified for primary end-point analysis. The characteristics of the patient population and their surgical procedures were similar. The overall rate of surgical-site infection was lower in the experimental group (11.1% center 1, 17.5% center 2; overall 15.5%) than in controls (14.3% center 1, 24.2% center 2, overall 20.4%), but the observed difference was not statistically significant (P = 0.451), even with respect to surgical-site infection grade 1 (superficial) versus grades 2 and 3, or grade 1 and 2 versus grade 3.ConclusionsThis randomized trial did not confirm a statistically significant superiority of Aquacel® Ag Hydrofiber dressing in reducing surgical-site infection after elective colorectal cancer surgery.Trial registrationClinicaltrials.gov: NCT00981110


Annals of Oncology | 2016

Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial

Nicola Fazio; Roberto Biffi; R. Maibach; S. Hayoz; S. Thierstein; Peter Brauchli; Jürg Bernhard; Roger Stupp; B. Andreoni; Giuseppe Renne; Cristiano Crosta; R. Morant; A. Chiappa; Fabrizio Luca; M. G. Zampino; Olivier Huber; A. Goldhirsch; F. de Braud; Arnaud Roth; Ugo Pace; Sabine Cenciarelli; Simonetta Pozzi; Emilio Bertani; S. Mura; Katia Lorizzo; G. Di Meglio; D. Ravizza; Sabrina Boselli; M. Matter; M. Richter

BACKGROUND Fluorouracil-based adjuvant chemotherapy in gastric cancer has been reported to be effective by several meta-analyses. Perioperative chemotherapy in locally advanced resectable gastric cancer (RGC) has been reported improving survival by two large randomized trials and recent meta-analyses but the role of neoadjuvant chemotherapy and optimal regimen remains to be determined. We compared a neoadjuvant with adjuvant docetaxel-based regimen in a prospective randomized phase III trial, of which we present the 10-year follow-up data. PATIENTS AND METHODS Patients with cT3-4 anyN M0 or anyT cN1-3 M0 gastric carcinoma, staged with endoscopic ultrasound, computed tomography, bone scan, and laparoscopy, were assigned to receive four 21-day/cycles of docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2)/day over days 1-14, either before (arm A) or after (arm B) gastrectomy. Event-free survival was the primary end point, whereas secondary end points included overall survival, toxicity, down-staging, pathological response, quality of life, and feasibility of adjuvant chemotherapy. RESULTS This trial was activated in November 1999 and closed in November 2005 due to insufficient accrual. Of the 70 enrolled patients, 69 were randomized, 34 to arm A and 35 to arm B. No difference in EFS (2.5 years in both arms) or OS (4.3 versus 3.7 years, in arms A and B, respectively) was found. A higher dose intensity of chemotherapy was observed in arm A and more frequent chemotherapy-related serious adverse events occurred in arm B. Surgery was safe after preoperative chemotherapy. A 12% pathological complete response was observed in arm A. CONCLUSION Docetaxel/cisplatin/fluorouracil chemotherapy is promising in preoperative setting of locally advanced RGC. The early stopping could mask the real effectiveness of neoadjuvant treatment. However, the complete pathological tumour responses, feasibility, and safe surgery warrant further investigation of a taxane-based regimen in the preoperative setting.


Ecancermedicalscience | 2013

The role of the robotic technique in minimally invasive surgery in rectal cancer

Paolo Bianchi; Fabrizio Luca; Wanda Petz; Manuela Valvo; Sabine Cenciarelli; Massimiliano Zuccaro; Roberto Biffi

Laparoscopic rectal surgery is feasible, oncologically safe, and offers better short-term outcomes than traditional open procedures in terms of pain control, recovery of bowel function, length of hospital stay, and time until return to working activity. Nevertheless, laparoscopic techniques are not widely used in rectal surgery, mainly because they require a prolonged and demanding learning curve that is available only in high-volume and rectal cancer surgery centres experienced in minimally invasive surgery. Robotic surgery is a new technology that enables the surgeon to perform minimally invasive operations with better vision and more intuitive and precise control of the operating instruments, promising to overcome some of the technical difficulties associated with standard laparoscopy. The aim of this review is to summarise the current data on clinical and oncological outcomes of minimally invasive surgery in rectal cancer, focusing on robotic surgery, and providing original data from the authors’ centre.


Revista Brasileira De Coloproctologia | 2011

Excisão total do mesorreto por técnica robótica: resultados cirúrgicos e oncológicos iniciais

Tiago Leal Ghezzi; Fabrizio Luca; Manuela Valvo; Sabine Cenciarelli; Simonetta Pozzi; Danilo Umana; Rroberto Biffi

OBJECTIVES: to evaluate the surgical and oncological outcomes of patients with extraperitoneal rectal cancer who underwent robotic total mesorectal excision (TEM). METHODS: from January 2007 to March 2010 a total of 60 patients were consecutively operated on through robotic technique. Data regarding surgical data and oncological outcomes were prospectively registered in a database. RESULTS: 35 men and 25 women underwent surgery. The mean age was 60.3 ± 11.7 years. Sphincter preserving surgery was possible in 52 patients. The mean number lymph node harvested was 18.7 ± 8.8 lymph nodes. The mean distal surgical margin was 2.9 ± 1.7 cm, while the radial margin was negative in all patients. The duration of postoperative follow-up was 14.3 months. Only one local recurrence was observed. The overall and the cancer-specific survival were respectively 97.6% and 98.3%. CONCLUSIONS: robotic TEM is feasible and safe. It is equal or superior to open and laparoscopic techniques in terms of morbidity and mortality rates, sphincter preservation rates and early oncological outcomes


Annals of Oncology | 2004

Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients

Roberto Biffi; Simonetta Pozzi; Alberto Agazzi; Ugo Pace; A. Floridi; Sabine Cenciarelli; V. Peveri; A. Cocquio; B. Andreoni; Giovanni Martinelli


Journal of Surgical Oncology | 2006

Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: Low morbidity and mortality rates in a single center series of 250 patients

Roberto Biffi; Antonio Chiappa; Fabrizio Luca; Simonetta Pozzi; Felice Lo Faso; Sabine Cenciarelli; Bruno Andreoni


International Journal of Colorectal Disease | 2011

Assessing appropriateness for elective colorectal cancer surgery: clinical, oncological, and quality-of-life short-term outcomes employing different treatment approaches

Emilio Bertani; Antonio Chiappa; Roberto Biffi; Paolo Bianchi; Davide Radice; Vittorio Branchi; Elena Cenderelli; Irene Vetrano; Sabine Cenciarelli; Bruno Andreoni

Collaboration


Dive into the Sabine Cenciarelli's collaboration.

Top Co-Authors

Avatar

Roberto Biffi

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Simonetta Pozzi

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Fabrizio Luca

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Bruno Andreoni

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Manuela Valvo

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Emilio Bertani

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Antonio Chiappa

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Angelica Sonzogni

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Davide Radice

European Institute of Oncology

View shared research outputs
Researchain Logo
Decentralizing Knowledge